Clinical evaluation of the molecular-based BD SARS-CoV-2/Flu for the BD MAX™ system.

ABSTRACT:

Background

COVID-19 and influenza (flu) share similar clinical symptoms. Therefore, differential detection of these viruses during the respiratory virus season will be an important component for proper patient triage, management, and treatment.

Objectives

Establish the diagnostic performance related to SARS-CoV-2 and Flu A/B detection for the BD SARS-CoV-2/Flu for BD MAX™ System ("MAX SARS-CoV-2/Flu") multiplex assay.

Materials and methods

Two hundred and thirty-five (235) retrospective nasopharyngeal specimens were obtained from external vendors. The BD BioGx SARS-CoV-2 Reagents for BD MAX™ System ("BioGx SARS-CoV-2″) and the Cepheid Xpert® Xpress Flu/RSV ("Xpert Flu/RSV") were utilized as reference methods.

Results

By reference methods, 52 specimens were SARS

SUBMITTER: Paradis S 

PROVIDER: S-EPMC8376527 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature